Amicus Therapeutics, Inc.
US ˙ NasdaqGM ˙ US03152W1099
DETTE SYMBOL ER IKKE LÆNGERE AKTIVT

SecurityFOLD / Amicus Therapeutics, Inc.
InstitutionCaptrust Financial Advisors
Latest Disclosed Ownership15,335 shares
Latest Disclosed Value $ 221,741
Captrust Financial Advisors reports 39.63% decrease in ownership of FOLD / Amicus Therapeutics, Inc.

On May 14, 2026 - Captrust Financial Advisors filed a 13F-HR form disclosing ownership of 15,335 shares of Amicus Therapeutics, Inc. (US:FOLD) valued at $221,744 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 25,400 shares of Amicus Therapeutics, Inc.. This represents a change in shares of -39.63% during the quarter. The current value of the position is $222,204 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F AMICUS THERAPEUTIC COM Stock 03152W109 15,335 -10,065 -39.63 222 -38.78 0.0004
2026-02-17 2025-12-31 13F AMICUS THERAPEUTIC COM Stock 03152W109 25,400 460 1.84 362 84.18 0.0007
2025-11-19 2025-09-30 13F AMICUS THERAPEUTICS INC COM Stock 03152W109 24,940 24,940 197 0.0004
2022-11-16 2022-09-30 13F AMICUS THERAPEUTICS INC COM Common Stock 03152W109 0 -248 -100.00 0 -100.00
2022-08-23 2022-06-30 13F/A-1 AMICUS THERAPEUTICS INC COM Common Stock 03152W109 248 -538 -68.45 3 -57.14 0.0000
2022-08-16 2022-06-30 13F AMICUS THERAPEUTICS INC COM COM 03152W109 248 -538 3 0.0000
2022-05-16 2022-03-31 13F AMICUS THERAPEUTICS COM 03152W109 786 577 276.08 7 250.00 0.0000
2022-02-14 2021-12-31 13F AMICUS THERAPEUTICS INC COM Common Stock 03152W109 209 0 0.00 2 0.00 0.0000
2021-11-16 2021-09-30 13F AMICUS THERAPEUTICS INC COM Common Stock 03152W109 209 30 16.76 2 0.00 0.0000
2021-08-16 2021-06-30 13F AMICUS THERAPEUTICS INC COM Common Stock 03152W109 179 -110 -38.06 2 -33.33 0.0000
2021-05-17 2021-03-31 13F AMICUS THERAPEUTICS INC COM Common Stock 03152W109 289 289 3 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.